TenX Keane Acquisition
Why Robinhood?
You can watch TENK and buy or sell other stocks, ETFs, and their options commission-free!About TENK
Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.
TENK Key Statistics
Stock Snapshot
With a market cap of 61.29M, TenX Keane Acquisition(TENK) trades at $0.58. The stock has a price-to-earnings ratio of -1.22.
On 2026-10-24, TenX Keane Acquisition(TENK) stock opened at —, reached a high of —, and a low of —.
TenX Keane Acquisition(TENK) shares are trading with a volume of 0, against a daily average of 48.41K.
In the last year, TenX Keane Acquisition(TENK) shares hit a 52-week high of $1.93 and a 52-week low of $0.49.
In the last year, TenX Keane Acquisition(TENK) shares hit a 52-week high of $1.93 and a 52-week low of $0.49.
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.